secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALIMERA SCIENCES INC (—)
CIK:        0001267602
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001267602-24-000029
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alimera Q1 revenue up 70% to $23M; adjusted EBITDA positive; reaffirms FY guidance
--------------------------------------------------------------------------------

- Net revenue $23.0M (+70% YoY); US $14.6M (+92%), International $8.5M (+42%).
- Net loss $6.3M vs $5.0M loss in Q1 2023; adjusted EBITDA positive $1.8M vs ($2.4M) loss.
- Global end user demand 4,028 units (+23% YoY). Reaffirms FY2024 revenue of $105M and ≥20% EBITDA margin.
- Completed enrollment in Synchronicity Study (YUTIQ for uveitis); first patient randomized in DRCR Retina Network study for radiation retinopathy.
- NICE recommends ILUVIEN for phakic DME patients in UK; increased term loan by $5M with SLR Capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267602/000126760224000029/0001267602-24-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267602/000126760224000029/alim-20240514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001267602-24-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer